Pgiam/iStock via Getty Images Investment Update Following my last publication on AdaptHealth Corp (NASDAQ:AHCO) in August last year, where I reiterated a hold rating (after revising this lower in June), shares are 20% in the red and trade at ~10x trailing earnings. That report, titled "A 4% return on capital doesn't sing undervalued" covered the relevant points and challenges to AHCO's investment debate, namely: AHCO is a capital-intensive producing <10% return on capital, and "this has translated into ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38399 AdaptHealth Corp. (Exact name of registrant as specified in its charter) Delaware 82-3677704 (State of Other Jurisdiction of incorporation or Organization) (I.R.S. Emp ...

Financial Data and Key Metrics - Net revenue for Q2 2024 was $806 million, a 1.6% increase compared to Q2 2023 [18] - Sleep revenue reached $322.4 million, up 6.5% year-over-year, with new starts increasing over 5% sequentially from Q1 [18] - Diabetes revenue was $151.2 million, down $17.7 million year-over-year, primarily due to tough comparables from 2023 [19] - Adjusted EBITDA for Q2 2024 was $165.3 million, reflecting a margin of 20.5%, slightly improved from Q1 [22] - Free cash flow for Q2 was $116.7 million, outperforming the target of $94 million [23] Business Line Performance - Sleep business saw strong resupply demand, with the resupply census reaching over 1.6 million patients [18] - Diabetes revenue faced challenges due to timing of system conversions in 2023, but the company expects a pickup in the second half of 2024 [19] - Respiratory revenue grew 3.3% year-over-year, driven by onboarding Humana patients and strong utilization [21] Market Performance - The company is focusing on three core markets: sleep, respiratory, and diabetes, with efforts to align sales forces and improve operational efficiency [11] - The company recently signed an agreement to sell non-core custom rehab technology assets, which represented about 1% of enterprise revenue [22] Strategic Direction and Industry Competition - The company is investing in talent, process improvement, and technology adoption to drive organic growth and simplify operations [9][10] - A new leadership role, Executive Vice President of Strategy and Healthcare Innovation, was created to focus on long-term sustainable growth and clinical relevance [12] - The company is exploring AI and automation to improve operational efficiency and patient experiences [14][15] Management Commentary on Operating Environment and Future Outlook - Management expressed optimism about the road ahead, emphasizing the importance of simplifying operations and delivering growth [16] - The company expects Q3 revenue to be flat sequentially, with adjusted EBITDA margin slightly down due to recent investments in people and technology [24] - Full-year guidance was updated, with net revenue expected to be in the range of $3.255 billion to $3.315 billion, and adjusted EBITDA between $660 million and $700 million [24] Other Important Information - The company is paying down debt, with a net leverage ratio now just under 3x, ahead of the goal to be under 3x by the end of 2024 [23] - The company is conducting low-cost AI experiments, which are showing promising results in customer and clinical documentation [14][15] Q&A Session Summary Question: Non-core assets and their potential impact - Non-core assets are those that do not support the company's focus on sleep, respiratory, and diabetes markets, and the company is evaluating their disposition [27][28] Question: Diabetes business trajectory and CGM performance - The company expects a pickup in pump and CGM revenue in the second half of 2024, driven by recent CGM compatibility launches [31][32] Question: Sleep business supply constraints - Supply constraints for sleep resupply products improved during Q2, and the company does not expect further issues for the rest of the year [43][44] Question: Investments and their impact on EBITDA guidance - The company made key investments in people and technology, which will impact Q3 EBITDA margin, but cost-out initiatives are expected to offset these in Q4 [51][52] Question: Diabetes revenue through pharmacy channels - Approximately 5% of diabetes revenue is going through pharmacy channels, with expectations for growth as the company expands its pharmacy distribution capabilities [54] Question: Respiratory revenue growth and capitated contracts - Respiratory revenue growth is driven by the Humana contract and market share gains, with the company maintaining a pipeline of incremental capitated deals [63][65] Question: Pharmacy channel infrastructure for diabetes products - The company is building infrastructure to support pharmacy distribution, with recent examples including Louisiana Medicaid [70][72]

AdaptHealth Corp. (AHCO) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.53%. A quarter ago, it was expected that this company would post earnings of $0.06 per share when it actually produced earnings of $0.02, delivering a surprise of -66.67%.Over the last four quarters, the compa ...

Exhibit 99.1 FOR IMMEDIATE RELEASE ADAPTHEALTH CORP. ANNOUNCES SECOND QUARTER 2024 RESULTS PLYMOUTH MEETING, Pa. – August 6, 2024 - AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the second quarter ended June 30, 2024. Second Quarter Results and Highlights All comparisons are to the quarter ended June ...

Investors interested in stocks from the Medical - Products sector have probably already heard of AdaptHealth Corp. (AHCO) and Prestige Consumer Healthcare (PBH) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors ...

Investors can contact the law firm at no cost to learn more about recovering their losses. LOS ANGELES, June 07, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm is investigating potential claims against the board of directors of AdaptHealth Corp (“AdaptHealth” or the “Company”) (NASDAQ: AHCO). AdaptHealth is a supplier of home medical equipment for chronic health conditions including diabetes, sleep apnea, and wound care. AdaptHealth sells medical devices directly to patients, and then bills patients’ insuran ...

Finding investing opportunities in the market might be challenging. Nevertheless, three equities stick out due to their ability to yield large profits during volatility. The first one sticks out due to its strong financial performance, which is characterized by considerable sales, margins, and profitability increases. The company’s growth trajectory and durability against market uncertainty make it a desirable investment for those looking for stability and upside potential in the electronic manufacturing se ...

cherrybeans/iStock via Getty Images In the past couple of years, there has been a major bust going on of stocks of companies that came public through SPACs in the 2018-2021 time period. The vast majority of the SPAC deals have struggled, and it has tainted the whole segment. But there are always those who not only survive, but thrive. AdaptHealth (NASDAQ:AHCO) is such a case. It is a rollup that initially struggled with digesting all of its acquisitions. The mergers have stopped, and the company has mad ...

] UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38399 AdaptHealth Corp. (Exact name of registrant as specified in its charter) Delaware 82-3677704 (State of Other Jurisdiction of incorporation or Organization) (I.R.S. ...